DRRX DURECT Corporation

1.94
+0.13  (7%)
Previous Close 1.81
Open 1.85
Price To book -194.00
Market Cap 285177276
Shares 146,998,596
Volume 690,490
Short Ratio 4.07
Av. Daily Volume 443,079

SEC filingsSee all SEC filings

  1. 8-K/A [Amend] - Current report 171115410
  2. 8-K - Current report 171113024
  3. 8-K - Current report 171093319
  4. CT ORDER - Confidential treatment order 171079678
  5. S-8 - Securities to be offered to employees in employee benefit plans 171018291

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial planned.
DUR-928
Primary sclerosing cholangitis (PSC)
CRL issued February 12, 2014.
Posidur
Post-operative pain relief
CRL Feb 12 2014. Phase 3 commenced November 2015 in response to CRL. Enrollment originally expected to take one year but the company announced ammendments to the trial on April 7, 2016, which will result in time added to complete the trial. Noted June 22, 2017 that enrollment has been completed with top-line data due 4Q 2017.
POSIMIR - PERSIST 3
Post-operative pain relief
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Phase 1b dosing progressed to higher dosage - announced October 31, 2016. Data presented at EASL April 24, 2017.
DUR-928
Nonalcoholic steatohepatitis (NASH)
CRL issued September 26, 2016. NDA to be resubmitted in 1Q 2018 following additional trials to be completed by the end of 2017.
Remoxy
Chronic pain

Latest News

  1. ETFs with exposure to DURECT Corp. : October 16, 2017
  2. Streetwise Reports Examines Small Biotech That Entered Patent Deal with British Company Targeting Schizophrenia
  3. DURECT Corp. :DRRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
  4. DURECT (DRRX): A $17.5 Million Patent Purchase Agreement with Indivior PLC
  5. DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase Agreement
  6. DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
  7. DURECT to Participate in Upcoming Healthcare Conferences
  8. Edited Transcript of DRRX earnings conference call or presentation 8-Aug-17 8:30pm GMT
  9. DRRX: A $293 Million Deal with Sandoz for POSIMIR® in the United States
  10. Durect reports 2Q loss
  11. DURECT Corporation Announces Second Quarter 2017 Financial Results and Provides Corporate Update
  12. ORADUR®-Methylphenidate ER Capsule Achieves Primary Endpoint in Phase 3 Study in ADHD in Taiwan
  13. DURECT Corporation Invites You to Join its Second Quarter 2017 Earnings Conference Call
  14. ETFs with exposure to DURECT Corp. : July 10, 2017
  15. Streetwise Reports Examines How Analysts Take Note as a Small-Cap Biotech Completes Early Enrollment for Phase 3 Trial
  16. DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR®
  17. Featured Company News - DURECT-SANDOZ Collaboration Clears HSR Review; Paves Path for POSIMIR Development and Marketing in the U.S.
  18. DURECT's Collaboration with Sandoz Clears HSR Review and is Effective
  19. ETFs with exposure to DURECT Corp. : May 26, 2017
  20. The Life Sciences Report Interviews H.C. Wainwright Analyst Ed Arce

SEC Filings

  1. 8-K/A [Amend] - Current report 171115410
  2. 8-K - Current report 171113024
  3. 8-K - Current report 171093319
  4. CT ORDER - Confidential treatment order 171079678
  5. S-8 - Securities to be offered to employees in employee benefit plans 171018291
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018166
  7. 8-K - Current report 171014920
  8. 8-K - Current report 171013939
  9. 8-K - Current report 171000980
  10. 8-K - Current report 17990027